Monte Rosa Therapeutics, Inc. announced that Owen Wallace, Ph.D., the Company?s Chief Scientific Officer will be departing from his position to transition to a Chief Executive Officer role at a UK-based biotechnology company. Dr. Wallace will serve as a scientific advisor to Monte Rosa, including as a member of its Scientific Advisory Board (SAB).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.16 USD | +4.26% | -15.96% | -26.37% |
May. 16 | Sector Update: Health Care Stocks Mixed in Late Afternoon Trading | MT |
May. 16 | Monte Rosa Therapeutics Prices $100 Million Public Offering | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.37% | 254M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+44.98% | 40.65B | |
-10.87% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- GLUE Stock
- News Monte Rosa Therapeutics, Inc.
- Monte Rosa Therapeutics, Inc. Announces Departure of Owen Wallace as Chief Scientific Officer and Transition to Member of its Scientific Advisory Board